"Iron Chelating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems.
Descriptor ID |
D007502
|
MeSH Number(s) |
D27.505.519.914.500.410 D27.720.832.500.410
|
Concept/Terms |
Iron Chelating Agents- Iron Chelating Agents
- Agents, Iron Chelating
- Chelating Agents, Iron
- Iron Chelates
- Chelates, Iron
|
Below are MeSH descriptors whose meaning is more general than "Iron Chelating Agents".
Below are MeSH descriptors whose meaning is more specific than "Iron Chelating Agents".
This graph shows the total number of publications written about "Iron Chelating Agents" by people in this website by year, and whether "Iron Chelating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2007 | 1 | 1 | 2 |
2009 | 2 | 0 | 2 |
2010 | 2 | 0 | 2 |
2012 | 2 | 0 | 2 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Iron Chelating Agents" by people in Profiles.
-
Sullivan KE, Lavin SR, Livingston S, Knutson M, Valdes EV, Warren LK. Safety and efficacy of a novel iron chelator (HBED; (N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis). J Anim Physiol Anim Nutr (Berl). 2022 Sep; 106(5):1107-1117.
-
Lin X, Ammosova T, Kumari N, Nekhai S. Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals. Curr Pharm Des. 2017; 23(28):4122-4132.
-
Kumari N, Iordanskiy S, Kovalskyy D, Breuer D, Niu X, Lin X, Xu M, Gavrilenko K, Kashanchi F, Dhawan S, Nekhai S. Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase I?B-a expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription. Antimicrob Agents Chemother. 2014 Nov; 58(11):6558-71.
-
Walcourt A, Kurantsin-Mills J, Kwagyan J, Adenuga BB, Kalinowski DS, Lovejoy DB, Lane DJ, Richardson DR. Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool. J Inorg Biochem. 2013 Dec; 129:43-51.
-
Debebe Z, Nekhai S, Ashenafi M, Lovejoy DB, Kalinowski DS, Gordeuk VR, Byrnes WM, Richardson DR, Karla PK. Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 01; 906:25-32.
-
Liu G, Men P, Zhu X, Perry G. Iron chelation and nanoparticle target delivery in the development of new multifunctional disease-modifying drugs for Alzheimer's disease. Ther Deliv. 2012 May; 3(5):571-4.
-
Debebe Z, Ammosova T, Breuer D, Lovejoy DB, Kalinowski DS, Kumar K, Jerebtsova M, Ray P, Kashanchi F, Gordeuk VR, Richardson DR, Nekhai S. Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol. 2011 Jan; 79(1):185-96.
-
Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol. 2010; 610:123-44.
-
Liu G, Men P, Perry G, Smith MA. Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog Brain Res. 2009; 180:97-108.
-
Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett. 2009 May 22; 455(3):187-90.